The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.
US8883745B2
申请人:——
公开号:US8883745B2
公开(公告)日:2014-11-11
The ester enolate Claisen rearrangement. Stereochemical control through stereoselective enolate formation
作者:Robert E. Ireland、Richard H. Mueller、Alvin K. Willard